



Amanta Healthcare Limited

Issue Dates - Opens: 01-09-2025 | Closes: 03-09-2025

IPO Note	<div>1. Amanta Healthcare Limited is a pharmaceutical company specializing in developing, manufacturing, and marketing sterile liquid parenteral products, using advanced Aseptic Blow-Fill-Seal and Injection Stretch Blow Moulding technologies.</div> <div>2. The Company manufactures IV fluids, diluents, ophthalmic solutions, and respiratory care products.</div>
Rating	★ ★ (Average)

IPO SNAPSHOT

Issue Size	₹126.00 Crores
Issue Type	Book Building IPO
Fresh Issue	₹126.00 Crores
Offer for Sale	-
Face Value Per Share	₹10
Price Band Per Share	₹120 to ₹126
Minimum Lot Size	119 Shares
Listing On	BSE, NSE
Basis of Allotment	04/09/2025
Credit of Shares to Demat A/C	05/09/2025
Listing Date	08/09/2025
Registrar to the Issue	<u>MUFG Intime India Pvt.Ltd.</u>

IPO SNAPSHOT- Amanta Healthcare Limited																																			
About the Company	<ul style="list-style-type: none">▪ Incorporated in 1994,▪ Amanta Healthcare Limited is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, being packed in plastic container with Aseptic Blow-Fill-Seal and Injection Strech Blow Moulding technology.▪ They manufacture large volume parenterals and small volume parenterals in six therapeutic segments.▪ In addition to that, they also manufacturer medical devices.▪ The Company manufacture fluid therapy - (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products like irrigation, first-aid solution, eye lubricants etc. in medical device segment.▪ They offer wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume ranging from 2ml to 1000 ml.▪ The Company markets its products through three strategic business units: (a) national sales, (b) international sales, and (c) product partnerships with various Indian and foreign pharmaceutical firms.▪ They manufacture diverse generics product portfolio of over 45 products and market them under their own brands in the Indian market through a network of over 320 distributors and stockists.																																		
Competitive Strengths	<ul style="list-style-type: none">▪ Well-established manufacturer of pharmaceutical formulations with a diverse product portfolio and diverse market.▪ Large manufacturing capabilities▪ Wide Domestic and International Marketing Network.▪ Experienced management team supported by a large, diverse and skilled workforce.																																		
Financials (₹ in Crores)	<table><tr><th>Particulars</th><th>31-3-2023</th><th>31-3-2024</th><th>31-03-2025</th><th>Y-o-Y</th></tr><tr><td>Revenue</td><td>259.1</td><td>280.3</td><td>274.7</td><td>-2%</td></tr><tr><td>EBITDA</td><td>52.7</td><td>57.4</td><td>59.6</td><td>4%</td></tr><tr><td>EBITDA Margin</td><td>20.4%</td><td>20.5%</td><td>21.7%</td><td></td></tr><tr><td>PAT</td><td>-2.1</td><td>3.6</td><td>10.5</td><td>190%</td></tr><tr><td>PAT Margin</td><td>-0.8%</td><td>1.2%</td><td>3.8%</td><td></td></tr></table>					Particulars	31-3-2023	31-3-2024	31-03-2025	Y-o-Y	Revenue	259.1	280.3	274.7	-2%	EBITDA	52.7	57.4	59.6	4%	EBITDA Margin	20.4%	20.5%	21.7%		PAT	-2.1	3.6	10.5	190%	PAT Margin	-0.8%	1.2%	3.8%	
Particulars	31-3-2023	31-3-2024	31-03-2025	Y-o-Y																															
Revenue	259.1	280.3	274.7	-2%																															
EBITDA	52.7	57.4	59.6	4%																															
EBITDA Margin	20.4%	20.5%	21.7%																																
PAT	-2.1	3.6	10.5	190%																															
PAT Margin	-0.8%	1.2%	3.8%																																
Valuation	<ul style="list-style-type: none">▪ Attributing Annualized FY25 Earnings asking P/E = 34.59																																		
Peers	<table><tr><th>Company Name</th><th>P/E ratio</th></tr><tr><td>Denis Chem Lab Limited</td><td>16.2</td></tr></table> <p>Note: P/E ratio is calculated as on 25th August, 2025</p>					Company Name	P/E ratio	Denis Chem Lab Limited	16.2																										
Company Name	P/E ratio																																		
Denis Chem Lab Limited	16.2																																		
Promoters	<ul style="list-style-type: none">▪ Bhavesh Patel▪ Vishal Patel▪ Jayshreeben Patel▪ Jitendrakumar Patel▪ Milcent Appliances Private Limited																																		
Objects of the issue	<ul style="list-style-type: none">▪ Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat.▪ Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat.▪ General corporate purposes.																																		
COMPILED & PREPARED BY SHAH INVESTOR’S HOME LTD ALL RIGHTS RESERVED																																			

LOTS	SHARES	PRICE
Retail		
1	119	14,994
2	238	29,988
3	357	44,982
4	476	59,976
5	595	74,970
6	714	89,964
7	833	1,04,958
8	952	1,19,952
9	1,071	1,34,946
10	1,190	1,49,940
11	1,309	1,64,934
12	1,428	1,79,928
13	1,547	1,94,922
S-HNI		
14(Min)	1,666	2,09,916
66(Max)	7,854	9,89,604
B-HNI		
67(Min)	7,973	10,04,598

DISCLAIMER

The information provided by or in this newsletter is generally from the press reports, electronic media, research websites and other media. It also includes information from interviews conducted, analysis, views expressed by our research team. Investors shouldnot rely solely on the information contained in this publication and must make their own investment decision based on their specific objectives and financial positions and using such independent advisor as they believe necessary. The material and the information provided herein are not and should not be construed as an advice to buy or sell any of the securities named in this newsletter. SIHL may or may not hold positions in any of the securities named in this newsletter as a part of its business. Past performance is not necessarily an indication of future performance. SIHL does not assure for accuracy and correctness of information of reports in this newsletter.

